Superworth

Teva Pharmaceutical Industries price to book ratio TEVA

Market value divided by the book value of the company's net assets, since 2018.

Today, Nov 3, 2026
6.4×
9-year median
1.2×
Against its 9-year history
100th
percentile: 0 is its lowest day, 100 its highest
9-year range
0.5× to 6.3×
Peer median
5.7×

Teva Pharmaceutical Industries' price to book ratio is 6.4× as of Nov 3, 2026.

That is above its 9-year median of 1.2×, higher than on 100% of days in the last 9 years.

Over that time it ranged from 0.5× in Aug 2019 to 6.3× in Oct 2026.

The median for 10 healthcare stocks of a similar size is 5.7×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far6.1×4.2×6.3×
20255.0×2.6×5.0×
20244.3×1.8×4.3×
20231.7×1.0×1.7×
20221.2×0.8×1.4×
20210.8×0.8×1.4×
20201.1×0.6×1.2×
20190.8×0.5×1.3×
20180.9×0.9×1.4×

Against its peers

Companies in Healthcare nearest Teva Pharmaceutical Industries' size, closest first, today.

CompanyPrice to book ratio
TEVATeva Pharmaceutical Industries6.4×
AAgilent Technologies6.7×
HUMHumana2.6×
MDLNMedlinen/m
WATWaters3.1×
IQVIQVIA6.9×
IDXXIDEXX Laboratories32.3×
EWEdwards Lifesciences5.1×
BDXBecton, Dickinson and2.2×
ONCBeOne Medicines7.8×
RPRXRoyalty Pharma5.7×
Peer median5.7×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Teva Pharmaceutical Industries

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.